Reason for request


No clinical benefit demonstrated by comparison with other antiepileptics in the treatment of partial onset seizures, with or without secondary generalisation, in patients aged 16 years or older


  • BRIVIACT has a Marketing Authorisation as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. 
  • Without a robust comparative study, BRIVIACT did not demonstrate clinical benefit compared with other antiepileptics.


Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments